login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

First patient enrolled in SCAFFOLD clinical study for carotid stenting


Thursday, 12 Sep 2013 10:09
Claudio Schönholz
Claudio Schönholz

Gore has announced that it has enrolled the first patient in its Carotid stent clinical study for the treatment of carotid artery stenosis in patients at increased risk for adverse events from carotid endarterectomy (SCAFFOLD). The patient was successfully treated by Claudio Schönholz and his team at the Medical University of South Carolina in Charleston, USA.


“The first procedure using the Gore carotid stent was successful and the patient is doing well, having left the hospital the next day. Studies like this will further our understanding of optimal patient outcomes in carotid artery stenosis,” Schönholz said. “The new Gore device is designed to be flexible, offer plaque retention and stabilisation benefits, and along with bound heparin may provide advantages for improved patient outcomes.”

SCAFFOLD is a multicentre, single-arm, prospective study comparing the Gore carotid stent to a performance goal developed from carotid endarterectomy outcomes. The investigational study will include up to 50 sites in the US and will enrol approximately 312 patients. Co-principal investigators are Peter Schneider, Kaiser Permanente Medical Center, Honolulu; and William Gray, Columbia University Medical Center, New York.

“In times of uncertainty regarding optimal treatment for patients with high surgical risks, it is important to evaluate unique treatment options,” said Schneider.

Leveraging more than 35 years of clinical experience with expanded polytetrafluoroethylene (ePTFE), the Gore carotid stent is a next-generation device designed to integrate innovative material to trap arterial plaque against the vessel wall, while yielding maximised flexibility of the stent in order to conform to the often tortuous anatomy of carotid vasculature. The new Gore device combines the flexible properties of a traditional open-cell, nitinol stent design with a 500 micron pore size ePTFE lattice which offers the plaque retention and stabilisation benefits traditionally seen in a closed cell stent design. Additionally, the permanently bound heparin may offer a local advantage seen with other Gore devices that utilise bound heparin.

“Gore is committed to continuing development of innovative solutions for patients in order to improve their quality of life,” said Ben Beckstead, associate with the Gore Medical Division Peripheral Interventional Business. “The Gore SCAFFOLD clinical study will bring us one step closer to a new solution for improving patient outcomes, while simultaneously generating data for consideration of Medicare reimbursement for such procedures.”




Add New Comment

Related Items


Most popular


New device allows brain to bypass spinal cord and move paralysed limbs
Friday, 27 Jun 2014
For the first time ever, a paralysed man has moved his fingers and hand with his own thoughts after an electronic neural bypass for spinal cord injuries that reconnects the brain directly to muscles, ... New device allows brain to bypass spinal cord and move paralysed limbs

FDA IDE approval for PulseRider
Tuesday, 10 Jun 2014
The IDE allows Pulsar Vascular to begin a multicentre clinical trial in support of a humanitarian device exemption (HDE) to evaluate the PulseRider for US approval for wide neck aneurysms at or near ... FDA IDE approval for PulseRider

ROADSTER trial studying new path to carotid revascularisation completes patient enrolment
Friday, 18 Jul 2014
The trial was the first of its kind to study the treatment of carotid artery stenosis by placing a stent via direct access to the common carotid artery in the neck in an entirely new minimally ... ROADSTER trial studying new path to carotid revascularisation completes patient enrolment

Features


Neuro-oncologic treatment for glioblastoma
Monday, 21 Jul 2014
Malignant gliomas are the most common type of primary malignant brain tumour, accounting for 80% of patients and an annual incidence of 5.26 per 100,000 population, or 17,000 new cases diagnosed per ... Neuro-oncologic treatment for glioblastoma

Early brain stimulation may help stroke survivors recover language function
Monday, 21 Jul 2014
Dieter Heiss, who presented on early brain stimulation for stroke patients at the 8th World Congress on Controversies in Neurology (CONy), 8–11 May, Berlin, Germany, writes for NeuroNews on how this ... Early brain stimulation may help stroke survivors recover language function

Profiles


William T Couldwell
Thursday, 24 Apr 2014
William T Couldwell is professor of neurosurgery in the Department of Neurological Surgery, U... William T Couldwell

Ali R Rezai
Monday, 10 Feb 2014
Ali R Rezai speaks to NeuroNews about his clinical and research career, which has been focused on ... Ali R Rezai

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions